Prosecution Insights
Last updated: November 20, 2026
Application No. 18/997,966

PHARMACEUTICAL DRY POWDER COMPOSITION AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS

Non-Final OA §102
Filed
Jan 23, 2025
Priority
Sep 02, 2022 — nonprovisional of PCTEP2022074500
Examiner
SONG, JIANFENG
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Liita Care Aps
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
492 granted / 872 resolved
-3.6% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
67 currently pending
Career history
952
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
48.5%
+8.5% vs TC avg
§102
10.2%
-29.8% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 872 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-24 are pending and under examination. Priority Acknowledge is made that this application is national stage of internation patent application PCT/EP2022/074500, filed on 09/02/2022. Information Disclosure Statement The information disclosure statement (IDS) submitted on 04/22/2025 is being considered by the examiner. Claim Objections Claims 4-24 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims 4-24 have not been further treated on the merits. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-3 are rejected under 35 U.S.C. 102(a)(1) & (a)(2) as being anticipated by Lipp et al. (US20150231066). The limitation of claim 1 is met by Lipp et al. disclosing a respirable dry powder comprising sodium chloride in an amount of 61% to about 90% for treating respiratory viral infection (claims 1, 12 and 14) and the dry powder is administered by inhalation to a subject (claims 8-9; [0053-0054]) such as human ([0252]). The limitation of for use in preventing and or treating a viral respiratory tract infection and administered to a mammalian subject by dry powder inhalation are also intended use, not limiting. Regarding claim 2, Lipp et al. disclose respiratory viral infection from coronavirus, and this is considered as intended use, not limiting. Regarding claim 3, since Lipp et al. disclosing treating respiratory viral infection, the composition must reduce the time for resolution of one or more symptoms caused by the viral respiratory tract infection. Since prior art discloses the same composition, the same composition must have the same property. MPEP 2112.01, "Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JIANFENG SONG. Ph.D. whose telephone number is (571)270-1978. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JIANFENG SONG/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Jan 23, 2025
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797322
REDUCTION OF OIL TRANSFER FROM SCALP TO HAIR WITH INCREASING POLARITY OF HAIR
3y 2m to grant Granted Nov 17, 2026
Patent 12773378
METHOD FOR THE COSMETIC TREATMENT OF KERATIN FIBRES COMPRISING A STAGE OF APPLICATION OF A RARE EARTH METAL COMPOSITION AND A STAGE OF APPLICATION OF A COMPOSITION COMPRISING SURFACTANTS
4y 4m to grant Granted Oct 27, 2026
Patent 12773382
BIOFILM REMOVER AND BIOFILM REMOVAL METHOD
2y 10m to grant Granted Oct 27, 2026
Patent 12766106
MICROPARTICLES CONTAINING MOXIDECTIN, AND PREPARATION METHOD THEREFOR
2y 8m to grant Granted Oct 20, 2026
Patent 12758519
FELINE FOOD COMPOSITION
5y 2m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
89%
With Interview (+32.8%)
2y 8m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 872 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month